WADA Prohibited List raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-02-27. Anything still debated is marked as such rather than presented as settled.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.
Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human therapeutic use | No marketing authorization identified in major jurisdictions. |
| Anti-doping class | PPARδ agonist; hormone and metabolic modulators | Listed on the WADA Prohibited List. |
| Common test matrix | Urine | Also blood and tissue in research settings. |
| Typical analytical method | LC-MS/MS | Targets parent compound and metabolites. |
| Major safety signal | Tumor findings in rodents | Human relevance not established; limited human data. |
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
Handling and quality assessment of cardarine reference material follow general laboratory practices for poorly characterized compounds. It typically appears as a white to off-white powder and is sparingly soluble in water but soluble in organic solvents such as dimethyl sulfoxide and ethanol. Storage recommendations usually specify a cool, dry, dark place, with long-term storage at low temperature and desiccation. Purity may be checked by high-performance liquid chromatography with ultraviolet detection, while identity is confirmed by mass spectrometry and nuclear magnetic resonance. No pharmacopeial monograph exists, so reported purity and stability depend on the supplier’s methods.
GW501516 acts as a selective agonist at PPARδ, a nuclear receptor that regulates transcription of genes involved in lipid handling and energy metabolism. Activation of PPARδ in preclinical models increases fatty acid oxidation, mitochondrial biogenesis, and exercise endurance in rodents. These effects have made the compound a subject of metabolic research and also a target for sport anti-doping rules. In humans, however, controlled studies are limited, and whether similar endurance or metabolic changes occur at tolerated exposures remains an open question. The receptor’s broad tissue distribution also means downstream effects may vary by organ and condition.
Detection of GW501516 in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. Urine is a common matrix in anti-doping analysis, while blood or plasma may be used in research settings. Sample preparation can involve enzymatic hydrolysis, protein precipitation, or solid-phase extraction before instrumental analysis. Because the compound undergoes metabolism, assays may target the parent molecule, one or more metabolites, or both. Detection windows are not fixed; they depend on factors such as dose, route, individual metabolism, and assay sensitivity. Reference standards are required for accurate identification and quantification.
== Study results == Eptifibatide was licensed due to the positive results of the so-called PURSUIT study encompassing 10,948 patients. In this study all patients had experienced either unstable angina or a non-ST-segment-elevation myocardial infarction. Significantly fewer patients developed a myocardial infarction under therapy with eptifibatide. Death rates showed a tendency in favor of eptifibatide, but this superiority was not statistically significant.
== Testing == The meat industry strives to produce meat with standardized and guaranteed tenderness, since these characteristics are sought for by the consumers. For that purpose a number of objective tests of tenderness have been developed, gauging meat resistance to shear force, most commonly used being Slice Shear Force test and Warner–Bratzler Shear Force test.
True muscle weakness (or neuromuscular weakness) describes a condition where the force exerted by the muscles is less than would be expected, for example muscular dystrophy. Perceived muscle weakness (or non-neuromuscular weakness) describes a condition where a person feels more effort than normal is required to exert a given amount of force but actual muscle strength is normal, for example myalgic encephalomyelitis/chronic fatigue syndrome. In some conditions, such as myasthenia gravis, muscle strength is normal when resting, but true weakness occurs after the muscle has been subjected to exercise. This is also true for some cases of chronic fatigue syndrome, where objective post-exertion muscle weakness with delayed recovery time has been measured and is a feature of some of the published definitions.
On 18 January 2024, Natalia Kanem, the executive director of the UN Population Fund, spoke at the World Economic Forum at Davos, stating the situation was the "worst nightmare" the UNPF representative had ever witnessed, as there were 180 women giving birth daily, sometimes on the streets of Gaza, as the territory's health system collapsed. On 17 January, Care International reported a 300 percent increase in the rate of miscarriage in Gaza since the start of Israel's bombing. UNICEF reported on 19 January that 20,000 babies had been born in the Gaza Strip since 7 October. UNICEF described each birth as a baby being "delivered into hell", and stated "humanity cannot allow this warped version of normal to persist any longer." The UN Women's agency reported that since the start of the conflict, two mothers in Gaza had been killed every hour, every day. WHO reported an increase in stress-induced stillbirths. Doctors Without Borders stated that women were giving birth in plastic tents, and that those undergoing C-sections were being released within hours. It also reported that women were being turned away from hospitals due to overcrowding, with some forced to birth in public restrooms. Doctors at Kamal Adwan Hospital performed an emergency c-section on a deceased pregnant woman in February 2024, after which they performed a fetal cardiac resuscitation; however, the baby did not survive.
In dental anatomy, the gingival fibers are the connective tissue fibers that inhabit the gingival tissue (gums) adjacent to teeth and help hold the tissue firmly against the teeth. They are primarily composed of type I collagen, although type III fibers are also involved. These fibers, unlike the fibers of the periodontal ligament, in general, attach the tooth to the gingival tissue, rather than the tooth to the alveolar bone.
Sources: en.wikipedia.org
There are varied reasons for e-cigarette use. Most users are trying to quit smoking, but some use is recreational or as an attempt to get around smoke-free laws. Many people vape to relax, and some because vaping is safer than smoking. The wide choice of flavors and lower price compared to cigarettes are also important factors. Other motivations include reduced odor and fewer stains. E-cigarettes also appeal to technophiles who enjoy customizing their devices.
28 December The New York Times published an analysis of a series of articles by Võ Nguyên Giáp published from 14 to 20 December in Nhân Dân where he outlined a move to better trained, highly mobile forces. This was seen as being a response to North Vietnamese manpower shortages and losses during the Tet Offensive.
== See also == Defibrotide - a similar mixture of DNA fragments purified from pig intestinal mucosa and used as an anticoagulant. Silk peptides - a mixture of hydrolysed silk proteins used for similar cosmetic applications.
Elagolix is taken by the oral route of administration, in contrast to other GnRH modulators. The oral bioavailability of elagolix in humans is not described in the Food and Drug Administration (FDA) label for the medication, but in animal research elagolix showed a low oral bioavailability of 5.8% in rats and 11% in monkeys. Following administration, elagolix is rapidly absorbed, with peak concentrations occurring after 0.5 to 1.5 hours. The drug accumulation ratio of elagolix at 150 mg once per day is 0.98 and at 200 mg twice per day is 0.89, indicating that it is not accumulated in the body with continuous administration. At steady state, peak levels of elagolix at 150 mg once per day are 574 ng/mL and at 200 mg twice per day are 774 ng/mL while area-under-the-curve levels of elagolix at 150 mg once per day are 1,292 ng•hour/mL and at 200 mg twice per day are 1,725 ng•hour/mL. A toxicology study found that levels of elagolix in women after a single dose of 1,200 mg were 17 times higher than in women taking 200 mg twice daily. Taking elagolix with a high-fat meal has been found to decrease its peak levels by 36% and its area-under-the-curve levels by 24%. In terms of distribution, the plasma protein binding of elagolix is 80% and its blood-to-plasma ratio is 0.6. The volume of distribution at steady state is 1,674 L at 150 mg once per day and 881 L at 200 mg twice per day. Elagolix is metabolized in the liver, with the major pathway being by CYP3A and minor pathways including by CYP2D6, CYP2C8, and UDP-glucuronosyltransferases.
"Homo neanderthalensis". The Smithsonian Institution. February 14, 2010. Human Timeline (Interactive) – Smithsonian, National Museum of Natural History (August 2016). "Neanderthal DNA". International Society of Genetic Genealogy. Archived from the original on June 17, 2006.: Includes Neanderthal mtDNA sequences GenBank records for H. s. neanderthalensis maintained by the National Center for Biotechnology Information (NCBI) Alex, Bridget (February 21, 2024). "What's Behind the Evolution of Neanderthal Portraits". SAPIENS. The Climate Chronicles, explores the impact of Pleistocene climate change on Neanderthals and other hominins.
Sources: en.wikipedia.org
=== Overview === Weather forecasts during CAD events are especially prone to inaccuracies. Precipitation type and daily high temperatures are especially difficult to predict. Numerical weather models tend to be more accurate in predicting the development of a CAD event, and less accurate in predicting their erosion. Manual forecasting can provide more accurate forecasts. An experienced human forecaster will use numerical models as a guide, but account for the model's inaccuracies and shortcomings.
In the following years, the Swedish Navy added another seven submarines in three different classes (Undervattensbåten No 2, Laxen, and Abborren class) using the same propulsion technology but fitted with true diesel engines rather than semidiesels from the outset. Since by that time, the technology was usually based on the diesel engine rather than some other type of combustion engine, it eventually came to be known as diesel–electric transmission. Like many other early submarines, those initially designed in Sweden were quite small (less than 200 tonnes) and thus confined to littoral operation. When the Swedish Navy wanted to add larger vessels, capable of operating further from the shore, their designs were purchased from companies abroad that already had the required experience: first Italian (Fiat-Laurenti) and later German (A.G. Weser and IvS). As a side-effect, the diesel–electric transmission was temporarily abandoned. However, diesel–electric transmission was immediately reintroduced when Sweden began designing its own submarines again in the mid-1930s. From that point onwards, it has been consistently used for all new classes of Swedish submarines, albeit supplemented by air-independent propulsion (AIP) as provided by Stirling engines beginning with HMS Näcken in 1988.
While many of the claims are based on scientifically based physiological or biochemical processes, their use in bodybuilding parlance is often heavily colored by bodybuilding lore and industry marketing and, as such, may deviate considerably from traditional scientific usages of the terms. In addition, ingredients listed have been found at times to be different from the contents. In 2015, Consumer Reports reported unsafe levels of arsenic, cadmium, lead, and mercury in several of the protein powders that were tested. In the United States, the manufacturers of dietary supplements do not need to provide the Food and Drug Administration with evidence of product safety prior to marketing. As a result, the incidence of products adulterated with illegal ingredients has continued to rise. In 2013, one-third of the supplements linked to liver damage in one study were adulterated with unlisted steroids. More recently, the prevalence of designer steroids with unknown safety and pharmacological effects has increased. In 2015, a CBC investigative report found that protein spiking (i.e., the addition of amino-acid filler to manipulate analysis) was not uncommon; however, many of the companies involved challenged these claims.
Uranium-235 makes up about 0.72% of natural uranium. Unlike the predominant isotope uranium-238, it is fissile, i.e., it can sustain a fission chain reaction. It is the only fissile isotope that is a primordial nuclide or found in significant quantity in nature. Uranium-235 has a half-life of 704 million years. It was discovered in 1935 by Arthur Jeffrey Dempster. Its fission cross section for slow thermal neutrons is about 584.3±1 barns. For fast neutrons it is on the order of 1 barn. At thermal energy levels, about 5 of 6 neutron absorptions result in fission and 1 of 6 result in neutron capture forming uranium-236. The fission-to-capture ratio improves for faster neutrons.
== Veterinary uses == The data from two six-month field studies and an extended use field study demonstrated that bexagliflozin was over 80% effective in improving glycemic control in cats with diabetes mellitus. Bexagliflozin, sold under the brand name Bexacat, is an antidiabetic medication used to improve glycemic control in cats with diabetes. Bexacat is the first sodium-glucose cotransporter 2 (SGLT2) inhibitor new animal drug approved by the US Food and Drug Administration (FDA) in any animal species. It was approved for medical use in the United States in December 2022. Bexacat is sponsored by Increvet Inc., based in Boston, Massachusetts. Elanco licensed development and commercialization rights for bexagliflozin from Bexcafe, an affiliate of Increvet.
Sources: en.wikipedia.org
No. Cardarine has not received approval for human therapeutic use in major jurisdictions. It remains an investigational compound.
It is classified as a PPARδ agonist on the WADA Prohibited List. Anti-doping laboratories can detect it and its metabolites in urine. Its use is banned in competition and usually out of competition.
Rodent studies reported increased tumor incidence at multiple sites. The human relevance remains uncertain, but the findings contributed to discontinuation of development. No long-term human cancer data are available.
Legal status varies by country. It is not approved as a medicine, and it is prohibited in sport. Some jurisdictions restrict import, sale, or possession.